Science Secretary Liz Kendall signed the UK-France Strategic Biomedical Alliance in Health and AI on Friday 29 May, the first bilateral science deal of its kind since Brexit1. The UK committed £894,000 to a supercomputing partnership linking Bristol's Isambard-AI, a UK National AI Supercomputer, with France's GENCI (Grand Equipement National de Calcul Intensif), the French national high-performance computing agency. A separate fund puts £300,000 a year from the UK alongside €330,000 from France into early-career researcher mobility2. Named partners include the University of Oxford, Universite Paris Cite, the Institut Pasteur, Imperial College London and France's national research agency, the CNRS (Centre National de la Recherche Scientifique), working on women's health, drug-resistant infections, malaria and emerging viruses.
The practical effect of the compute link is that UK biomedical AI researchers gain access to French capacity, and French teams to British, years before any of that work could spin out into a company. Researcher mobility funding partially reopens the EU talent pipeline that Brexit constrained, letting early-career scientists move between the two systems on funded placements rather than visas and grant applications.
This is the research-infrastructure floor beneath the startup economy, the layer that feeds the spinout pipeline long before any Series A. It follows the same instrument logic as the £2bn quantum commitment that anchored ProQure earlier in the topic: a targeted state cheque into shared infrastructure rather than into individual firms. The sums look small against a major venture round, but shared compute and funded mobility are what produce the founders who raise those rounds a decade later. The alliance also sidesteps the multilateral negotiation that UK association to Horizon Europe required in 2024, operating as a narrower bilateral instrument below the threshold of a formal UK-EU framework.
